NeurologyOnline.net

Neurology Xagena

Search results for "Alemtuzumab"

Two-year interim results from a Phase 2 trial comparing MabCampath ( Alemtuzumab; Campath ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have demonstrated statistically si ...


The results from the Lemtrada ( Alemtuzumab ) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis were published in The Lancet.In CARE-MS I and CARE-MS II, ...


Alemtuzumab ( Lemtrada ), an anti-CD52 monoclonal antibody, has increased the risk of thyroid dysfunction in CAMMS223, a phase 2 trial in relapsing-remitting multiple sclerosis. The objective of th ...


More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing- ...


New magnetic resonance imaging ( MRI ) data from the Lemtrada ( Alemtuzumab ) clinical development program were presented at the 66th American Academy of Neurology ( AAN ) Annual Meeting. In Alemtuzu ...


Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...


The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with relapsing forms of multiple sclerosis ( MS ). Because of its safety profile, the use o ...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...